KwokHing personal page - To The Moon

KwokHing

KwokHing

No personal profile

0Follow

2Followers

0Topic

0Badge

2022-06-21

K

@TechnicalHunter:2 Ways to Confirm a Market Bottom & 3 Levels to Buy

2022-04-20

Posting for chances

2022-04-19

For easter hunt chance

2022-04-18

Posting for easter egg change

2022-04-17

Posting for easter chance

2022-04-16

Any good stocks to recommend?

2022-04-15

Test test

2022-04-14

Great ariticle, would you like to share it?

@TigerEvents:🏆【GAME】Hunting Eggs for Extra Saving!

2021-07-14

Urm

Apple's potential 'buy now, pay later' plan sends sector shares tumbling

2021-06-21

?? ??

Orphazyme rose more than 6% in premarket trading

2021-04-17

Urm

Einhorn: "The Market Is Fractured And In The Process Of Breaking Completely"

2021-04-17

Can consider

The Smartest Stocks to Buy With $200 Right Now

2021-04-17

Can consider

The Smartest Stocks to Buy With $200 Right Now

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581737440579845","uuid":"3581737440579845","gmtCreate":1618643416512,"gmtModify":1618654286875,"name":"KwokHing","pinyin":"kwokhing","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":0,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9049293753,"gmtCreate":1655795467872,"gmtModify":1676535706979,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049293753","repostId":"9049202900","repostType":1,"repost":{"id":9049202900,"gmtCreate":1655794295752,"gmtModify":1676535706826,"author":{"id":"3448793367875557","authorId":"3448793367875557","name":"TechnicalHunter","avatar":"https://static.tigerbbs.com/20616c062c392e47ee8fc9107f46437d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3448793367875557","authorIdStr":"3448793367875557"},"themes":[],"title":"2 Ways to Confirm a Market Bottom & 3 Levels to Buy","htmlText":"When the Market will hit Bottom? <a href=\"https://ttm.financial/TW/9049202900\" target=\"_blank\">2 Ways to Comfirm &amp; 3 Levels to Watch</a>U.S. stocks and other stock markets fell last week after raising interest rates.The S&amp;P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&amp;P has fallen more than 23% since its January 2022 high.&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a>&nbsp;decreased&nbsp;4.78%,&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a>&nbsp;declined&nbsp;4.79%,&nbsp;YTD&nbsp;performance&nbsp;of&nbsp;each&nbsp;are,&nbsp;-24.7%,&nbsp;-17.5%&nbsp;respectively.<a target=\"_blank\" href=\"https://laohu8.com/S/XJO.AU\">$S&amp;P/ASX 200(XJO.AU)$</a> Last week performed the worst week","listText":"When the Market will hit Bottom? <a href=\"https://ttm.financial/TW/9049202900\" target=\"_blank\">2 Ways to Comfirm &amp; 3 Levels to Watch</a>U.S. stocks and other stock markets fell last week after raising interest rates.The S&amp;P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&amp;P has fallen more than 23% since its January 2022 high.&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a>&nbsp;decreased&nbsp;4.78%,&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a>&nbsp;declined&nbsp;4.79%,&nbsp;YTD&nbsp;performance&nbsp;of&nbsp;each&nbsp;are,&nbsp;-24.7%,&nbsp;-17.5%&nbsp;respectively.<a target=\"_blank\" href=\"https://laohu8.com/S/XJO.AU\">$S&amp;P/ASX 200(XJO.AU)$</a> Last week performed the worst week","text":"When the Market will hit Bottom? 2 Ways to Comfirm & 3 Levels to WatchU.S. stocks and other stock markets fell last week after raising interest rates.The S&P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&P has fallen more than 23% since its January 2022 high. $NASDAQ(.IXIC)$ decreased 4.78%, $DJIA(.DJI)$ declined 4.79%, YTD performance of each are, -24.7%, -17.5% respectively.$S&P/ASX 200(XJO.AU)$ Last week performed the worst week","images":[{"img":"https://community-static.tradeup.com/news/5403fbc4d0d6ccf9f5cc97050aa533e4","width":"1035","height":"201"},{"img":"https://community-static.tradeup.com/news/a3970d0e3842c3b440ced19bb2f56166","width":"664","height":"415"},{"img":"https://community-static.tradeup.com/news/18b0bdfae0727f344fe9d1993ba9e17b","width":"1240","height":"810"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049202900","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":562,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088721555,"gmtCreate":1650384858926,"gmtModify":1676534711047,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for chances","listText":"Posting for chances","text":"Posting for chances","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088721555","isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088553009,"gmtCreate":1650368085917,"gmtModify":1676534706244,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"For easter hunt chance","listText":"For easter hunt chance","text":"For easter hunt chance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088553009","isVote":1,"tweetType":1,"viewCount":947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088090246,"gmtCreate":1650287811041,"gmtModify":1676534686938,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for easter egg change","listText":"Posting for easter egg change","text":"Posting for easter egg change","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088090246","isVote":1,"tweetType":1,"viewCount":1007,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081979173,"gmtCreate":1650188135864,"gmtModify":1676534665863,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for easter chance","listText":"Posting for easter chance","text":"Posting for easter chance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081979173","isVote":1,"tweetType":1,"viewCount":756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9083842898,"gmtCreate":1650097378570,"gmtModify":1676534647348,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Any good stocks to recommend?&nbsp;","listText":"Any good stocks to recommend?&nbsp;","text":"Any good stocks to recommend?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9083842898","isVote":1,"tweetType":1,"viewCount":954,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089442933,"gmtCreate":1650027803960,"gmtModify":1676534631595,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Test test","listText":"Test test","text":"Test test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089442933","isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089921783,"gmtCreate":1649946588253,"gmtModify":1676534612985,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089921783","repostId":"9016476123","repostType":1,"repost":{"id":9016476123,"gmtCreate":1649229403658,"gmtModify":1676534474180,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"🏆【GAME】Hunting Eggs for Extra Saving!","htmlText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","listText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","text":"Tiger has prepared some Easter gifts for you, please click here to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","images":[{"img":"https://community-static.tradeup.com/news/15b435c0d10e0e89ad3e06b7bbd04830","width":"2251","height":"1334"},{"img":"https://community-static.tradeup.com/news/ff9640a9df2f24446e07b7a9b658cb4b","width":"1200","height":"630"},{"img":"https://community-static.tradeup.com/news/795038848b7c7b1d7dda27d92b580946","width":"1656","height":"948"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016476123","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144027308,"gmtCreate":1626255579104,"gmtModify":1703756436600,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Urm","listText":"Urm","text":"Urm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/144027308","repostId":"1176184294","repostType":4,"repost":{"id":"1176184294","kind":"news","pubTimestamp":1626254217,"share":"https://ttm.financial/m/news/1176184294?lang=&edition=fundamental","pubTime":"2021-07-14 17:16","market":"us","language":"en","title":"Apple's potential 'buy now, pay later' plan sends sector shares tumbling","url":"https://stock-news.laohu8.com/highlight/detail?id=1176184294","media":"Reuters","summary":" -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.The U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.The prospect of going up against a behemoth like Apple, as well a","content":"<p>(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.</p>\n<p>The U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.</p>\n<p>The prospect of going up against a behemoth like Apple, as well as other entrants including PayPal, was likely to test Australian pure-play BNPL firms that have so far gone unchallenged in a fertile U.S. market.</p>\n<p>Shares of Australia-listed Afterpay, the country’s biggest BNPL provider which derives a big chunk of its revenue from the United States, dived nearly 10% on Wednesday.</p>\n<p>Smaller rivals Zip Co Ltd and Sezzle fell sharply. Nasdaq-listed Affirm Holdings Inc tumbled more than 14% on Tuesday following the Bloomberg report and closed 10.5% lower.</p>\n<p>Apple Pay is a bigger threat than potential offerings from banks or credit companies given its wide reach and superior consumer experience on a mobile website or in-store, a client note by Citi analysts said.</p>\n<p>The BNPL industry has boomed as online shopping picked up pace during the global health crisis, with the number of merchants in the United States adding the repayment option nearly tripling in 2020, according to a McKinsey report.</p>\n<p>In Australia, where the regulation of the fast-growing sector is light and adoption is higher compared to other markets, a Deloitte report said 30% of the consumers in the country have a BNPL account.</p>\n<p>The sector’s fast-paced growth attracted Swedish firm Klarna, which has emerged as a major rival in Australia, and caught the attention of mainstream U.S. companies.</p>\n<p>U.S. payments giant PayPal launched its service in Australia on Wednesday and raised the ante by saying it would do away with late fees, an area that had earned Afterpay close to A$70 million ($52.23 million) in fiscal 2020.</p>\n<p>The Bloomberg report said Apple Pay users would be allowed to split their payments into four interest-free instalments, or across several months with interest - a model similar to rivals Klarna, Afterpay, Zip’s Quadpay and Affirm.</p>\n<p>A Goldman Sachs spokesperson declined to comment, while Apple was not available for comment.</p>\n<p>Afterpay said competition reinforces the significance of the sector and that each BNPL player operates a different model and generate revenue in different ways.</p>\n<p>A Zip spokesman said Apple’s reported move validated the company’s business where it was growing customer numbers despite increased competition.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple's potential 'buy now, pay later' plan sends sector shares tumbling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple's potential 'buy now, pay later' plan sends sector shares tumbling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 17:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic ...</p>\n\n<a href=\"https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","PYPL":"PayPal"},"source_url":"https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176184294","content_text":"(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.\nThe U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.\nThe prospect of going up against a behemoth like Apple, as well as other entrants including PayPal, was likely to test Australian pure-play BNPL firms that have so far gone unchallenged in a fertile U.S. market.\nShares of Australia-listed Afterpay, the country’s biggest BNPL provider which derives a big chunk of its revenue from the United States, dived nearly 10% on Wednesday.\nSmaller rivals Zip Co Ltd and Sezzle fell sharply. Nasdaq-listed Affirm Holdings Inc tumbled more than 14% on Tuesday following the Bloomberg report and closed 10.5% lower.\nApple Pay is a bigger threat than potential offerings from banks or credit companies given its wide reach and superior consumer experience on a mobile website or in-store, a client note by Citi analysts said.\nThe BNPL industry has boomed as online shopping picked up pace during the global health crisis, with the number of merchants in the United States adding the repayment option nearly tripling in 2020, according to a McKinsey report.\nIn Australia, where the regulation of the fast-growing sector is light and adoption is higher compared to other markets, a Deloitte report said 30% of the consumers in the country have a BNPL account.\nThe sector’s fast-paced growth attracted Swedish firm Klarna, which has emerged as a major rival in Australia, and caught the attention of mainstream U.S. companies.\nU.S. payments giant PayPal launched its service in Australia on Wednesday and raised the ante by saying it would do away with late fees, an area that had earned Afterpay close to A$70 million ($52.23 million) in fiscal 2020.\nThe Bloomberg report said Apple Pay users would be allowed to split their payments into four interest-free instalments, or across several months with interest - a model similar to rivals Klarna, Afterpay, Zip’s Quadpay and Affirm.\nA Goldman Sachs spokesperson declined to comment, while Apple was not available for comment.\nAfterpay said competition reinforces the significance of the sector and that each BNPL player operates a different model and generate revenue in different ways.\nA Zip spokesman said Apple’s reported move validated the company’s business where it was growing customer numbers despite increased competition.","news_type":1},"isVote":1,"tweetType":1,"viewCount":933,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167674161,"gmtCreate":1624267978453,"gmtModify":1703831989964,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"?? ??&nbsp;","listText":"?? ??&nbsp;","text":"?? ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/167674161","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1},"isVote":1,"tweetType":1,"viewCount":793,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379994901,"gmtCreate":1618649126403,"gmtModify":1704713823086,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Urm","listText":"Urm","text":"Urm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379994901","repostId":"1156411249","repostType":4,"repost":{"id":"1156411249","kind":"news","pubTimestamp":1618562497,"share":"https://ttm.financial/m/news/1156411249?lang=&edition=fundamental","pubTime":"2021-04-16 16:41","market":"us","language":"en","title":"Einhorn: \"The Market Is Fractured And In The Process Of Breaking Completely\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1156411249","media":"zerohedge","summary":"In many ways, David Einhorn's Greenlight appears to be back to its \"new normal\" - in a letter sent t","content":"<p>In many ways, David Einhorn's Greenlight appears to be back to its \"new normal\" - in a letter sent to investors, Einhorn writes that Greenlight again underperformed the market and returned -0.1% in the first quarter, badly underperforming the 6.2% return for the S&amp;P 500 index, before proceeding to bash the Fed, broken markets, Chamath and Elon, the basket of short stocks and much more.</p><p>That said, even though as Einhorn writes Greenlight made only a handful of portfolio changes and essentially broke even, \"a lot happened. In general, the investment environment – especially from mid-February through the end of the quarter – was favorable as value outperformed growth, and interest rates and inflation expectations rose.\"</p><p>He then asks if the tide has<i><b>finally</b></i>turned from Growth to Value, noting that \"after a very tough decade, we have only just begun a recovery as shown in this 45-year chart from Goldman Sachs research:\"</p><p><img src=\"https://static.tigerbbs.com/a5db342a0e7b68b8405ce6d4041b71a0\" tg-width=\"500\" tg-height=\"339\" referrerpolicy=\"no-referrer\">Part of the shift from growth to value, Einhorn writes, may be coming from higher inflation and inflation expectations. As measured by the inflation swap market, 10-year inflation expectations fell from 2.9% in September 2012 to 0.8% in March 2020. The only significant intervening bounce came in 2016, when expectations jumped from 1.5% to 2.3% on expectations of a major stimulus deal from the Trump admin (which never materialized). It is hardly a coincidence that that was the only year in the last decade in which value outperformed growth, as the Greenlight head notes. Fast forward to now, when after bottoming in March 2020, inflation expectations have recovered to 2.5%. The trend became clearer in the middle of May, and value started outperforming growth then, and especially since the middle of February. Indeed, aince May 15, the value-heavy Greenlight returned 80% of the S&amp;P 500 index with half the net exposure.</p><p>Einhorn is even more optimistic about the future when it comes to the \"growth to value\" rotation:</p><blockquote><i>When the time comes, we will have to figure out how to perform better in deflationary periods. But for now, we believe inflation is only going one way – higher – and we are optimistic about our prospects. The wind is now at our backs. The economy is in full recovery mode. Household balance sheets are stronger than they have been in a long time and household income growth was up 13% in February compared to last year. And this is before the latest $1.9 trillion – with a “T” – pandemic relief stimulus. Corporate capital spending is booming. There are shortages and bottlenecks everywhere. Last month nearly one million jobs returned. There are signs of an emerging labor shortage.</i></blockquote><p>As for the Fed, the Greenlight boss writes that \"it fundamentally changed its framework last August. It no longer seems to care that monetary policy works with a lag. Actually, it has embraced an asymmetrical inflation policy: The Fed wants to be ahead of the curve on the downside to protect<s>the stock market and corporate bondholders</s>the economy. Behind the curve is fine on the way up no matter how frothy the stock market the recovery is. Now, it says it is only going to react to actual inflation that exceeds its 2% target for a period of time.\"</p><p>The letter then goes on to muse how the Fed will know when it is blowing the next bubble, and to stop:</p><blockquote><i>... the Fed has indicated that it believes any abnormally high inflation will be transitory. We wonder, how will the Fed know?</i> <i><b>Do price increases come with a label that says “transitory”?</b></i> <i>Our sense is that no matter how hot inflation gets in the coming months, the Fed will continue with zero interest rates and large-scale asset purchases. After all, the U.S. Treasury has a lot of debt to sell and it isn’t clear who, other than the Fed, can absorb the supply.</i></blockquote><p>It's not just Powell who is throwing caution to the wind: so are such mainstream econ \"experts\" as John Oliver:</p><blockquote><i>The bipartisan idea that deficits don’t matter has even reached popular culture. John Oliverdedicated an entire episodeof Last Week Tonight to browbeating anyone who is concerned about the growing national debt. His argument boiled down to: (1) nobody knows how much debt is too much; (2) we have a good need to spend money now; and (3) it won’t be a problem until inflation shows up, and we can deal with it then.</i></blockquote><p>To this, Einhorn's response is simple: \"Though one can debate whether the official government statistics are contrived to avoid capturing inflation\" - and as we have repeatedly noted, inflation is now decidedly a political measurement, one which has been gamed for decades to make it appears as low as possible \"shortages and bottlenecks accompanied by rising demand can only be solved through increased capacity and higher prices. We have also reset the baseline income for non-working adults; it will take higher wages to bring those marginally attached to the labor force back to work.\"</p><p>Concluding this part of the letter, Einhorn writes that while the Fed says it has the tools to fight inflation (and according to Bernanke can cut it in<i>15 minutes</i>), \"it remains to be seen if it will have the stomach to use them when the time comes. That<b>is a discussion for another day. Right now, we remain positioned for rising inflation and inflation expectations.</b>\"</p><p>The Greenlight letter then goes on to lay out just how it plans to capture these rising inflation expectations, listing its top positions as follows, and how they performed in the frist quarter:</p><ul><li><b>Brighthouse Financial (BHF, +22%)</b>benefitted from rising interest rates;</li><li><b>Danimer Scientific (DNMR, +61%)</b>began its life as a public company;</li><li><b>Concentrix (CNXC, +52%)</b>benefitted from strong demand and rising estimates;</li><li><b>Resideo Technologies (REZI, +33%)</b>was helped by the strong housing market;</li><li><b>Change Healthcare (CHNG, +18%)</b>agreed to be acquired by UnitedHealthcare;</li><li><b>AerCap Holdings (AER, +29%)</b>agreed to acquire GE Capital’s aircraft leasing business (GECAS) at a discount; and</li><li><b>An undisclosed healthcare short (-41%)</b>fell due to reduced government reimbursement for its product.</li></ul><p><i>(incidentally, at quarter-end, Greenlight's largest disclosed long positions were Atlas Air Worldwide, Brighthouse Financial, Change Healthcare, Danimer Scientific and Green Brick Partners, with a net average exposure of 118% long and 81% short).</i></p><p>Which is not to say that there were no glitches. One was underperformance by homebuilder and land-developer GRBK, the fund's largest position (more on this in the full letter below). The other performance drag was - as usual- Greenlight's \"short basket\" of bubble stocks.</p><p>What follows next is a tour de force from Einhorn lashing out at all the ways the market is broken, and how the Reddit insanity of Q1 exposed it for all to see:</p><blockquote><i>In late January, the market came to focus on companies with large short interests. Despite having a diversified portfolio, a number of our positions fell into this group and experienced sudden, sharp rises. We adjusted to the dynamic by reducing our exposure to single name shorts, both in number and sizing. To mitigate the potentially uncomfortable net long bias that would have resulted, we added macro hedges of market index and index option shorts. While we do not expect this to be a permanent change, we will evaluate and modify as we go.</i> <i><b>The performance of our short portfolio in 2020 and in early 2021 was unacceptable, so change is certainly needed.</b></i> <i>If we swing a little less hard, we should hit more balls. We have also revised our internal analyst incentive structure to fully emphasize alpha creation.Much has been made of the short-squeezes in late January. In fact, Congress held hearings, where it called the leaders of Robinhood, Melvin Capital and Citadel and an individual investor who made a great call on GameStop (GME) to testify. We have a few thoughts about this to share.</i> <i><b>First, it is very healthy for market participants to discuss and debate stocks.</b></i> <i>This is true both privately and publicly. There are rules about fraud and manipulation that need to be followed,</i> <i><b>but investors discussing why they think GME (or any other stock) should go up or down ought to be encouraged. There is no reason to drag anyone before Congress for making a stock pick.</b></i> <i>Second, it is also fine to make bad stock picks.</i> <i><b>If a hedge fund takes a big position in a stock and is wrong, it loses money. Isn’t this how it is supposed to work?</b></i> <i>Third,</i> <i><b>payment for order flow is just disguised commissions.</b></i> <i>We are in a world where consumers, especially young ones, expect internet services to be free, or at least free to them. A quote widely attributed to Richard Serra about commercial TV in 1973 says it best: “You’re not the customer; you’re the product.”</i> <i><b>If you want the broker to work for you, pay a commission.</b></i> <i>Fourth, Robinhood suspended trading in certain stocks because it was undercapitalized. It is possible that it wasn’t following the regulatory requirements. A regulatory sanction is probably appropriate – but as we’ll discuss below, we won’t be holding our breath.</i></blockquote><p>The punchline:<i>Einhorn slamming Chamath and Elon for pouring the \"real jet fuel\" on the GME squeeze:</i></p><blockquote><i>Finally, we note that the real jet fuel on the GME squeeze came from Chamath Palihapitiya and Elon Musk, whose appearances on TV and Twitter, respectively, at a critical moment further destabilized the situation.</i> <i><b>Mr. Palihapitiya controls SoFi, which competes with Robinhood, and left us with the impression that by destabilizing GME he could harm a competitor.</b></i> <i>As for Mr. Musk,</i> <i><b>we are going to defend him, half-heartedly. If regulators wanted Elon Musk to stop manipulating stocks, they should have done so with more than a light slap on the wrist when they accused him of manipulating Tesla’s shares in 2018. The laws don’t apply to him and he can do whatever he wants.</b></i> <i>Many who would never support defunding the police have supported – and for all intents and purposes have succeeded – in almost completely defanging, if not defunding, the regulators. For the most part, quasi-anarchy appears to rule in markets.</i> <i><b>Sure, Dr. Michael Burry, famed for his role in The Big Short, reportedly received a visit from the SEC after tweeting warnings about recent market trends – and decided to stop publicly speaking truth to power. But for the most part, there is no cop on the beat.</b></i> <i>It’s as if there are no financial fraud prosecutors; companies and managements that are emboldened enough to engage in malfeasance have little to fear.</i></blockquote><p>Einhorn then concludes with three anecdotes to demonstrate his argument that this is not only an \"anything goes\" market where crime is rampant, but proving just how broken the market has become.</p><p>First, consider the investigation of Tether by the Office of the Attorney General of New York (OAG). As Einhorn explains, \"tether is a cryptocurrency that is always worth a dollar (the value is “tethered” to the dollar). Tether is one of the largest cryptocurrencies with about $40 billion outstanding, yet it has not been audited or regulated in any serious manner. In theory, Tether is supposed to have $1 of cash backing every Tether issued. Except it didn’t, at least when it was investigated.\" Incidentally, for anyone still confused, Tether is how theChinese launder billions in domestic funds abroad and outside the Chinese firewallas we explained in December, although so far few have the desire to expose this reality. In any case, here is Einhorn's lament:</p><blockquote><i>The OAG conducted a two-year probe and found that Tether deceived clients and the market by overstating reserves and hiding approximately $850 million of losses around the globe. Tether and its sponsor, Bitfinex, “recklessly and unlawfully covered up massive financial losses to keep their scheme going and protect their bottom lines,” said the OAG. Further, “Tether’s claims that its virtual currency was fully backed by U.S. dollars at all times was a lie.”Did the OAG shut down Tether? Did anyone get arrested or even lose their job? Was the regulatory infrastructure changed to make sure this doesn’t happen again? No, of course not. The OAG assessed an $18.5 million penalty and Tether agreed to discontinue “any trading activity with New Yorkers.” It was as if Bernie Madoff had been told to pay a small fine and stop ripping off New Yorkers, but to go ahead and have fun with the Palm Beach crowd.</i></blockquote><p>Einhorn next highlights one of the stocks most hated by the bearish community: GSX:</p><blockquote>The media is focused on how the banks allowed excessive leverage and poorly (or properly) managed their risks. The real story is how Arch-Egos was able to buy up most of the float of GSX Techedu, <b>causing the stock to soar 400% in the face of unrefuted allegations of massive fraud.</b>The SEC has an ongoing investigation of GSX but appears to not have noticed a single fund (or a small group of funds) essentially cornering the market. A traditionalist could say this was market manipulation and transparently illegal.</blockquote><p>The professional poker player finally points out some of the insane moves observed in pennystocks in Q1, focusing on a tiny deli owner in rural NJ:</p><blockquote><i>Strange things happen to all kinds of stocks. Last year, on one day in June, the stocks of about a dozen bankrupt companies roughly doubled on enormous volume. Recently, the Wall Street Journal reported a boom in penny stocks.Someone pointed us to Hometown International (HWIN), which owns a single deli in rural New Jersey. The deli had $21,772 in sales in 2019 and only $13,976 in 2020, as it was closed due to COVID from March to September.</i> <i><b>HWIN reached a market cap of $113 million on February 8.</b></i> <i>The largest shareholder is also the CEO/CFO/Treasurer and a Director, who also happens to be the wrestling coach of the high school next door to the deli. The pastrami must be amazing. Small investors who get sucked into these situations are likely to be harmed eventually, yet the regulators – who are supposed to be protecting investors – appear to be neither present nor curious.</i></blockquote><p>We don't find it at all surprising that Einhorn's conclusion from his capital markets observations over the past quarter is<i>identical</i>to ours, when we discussed the insane stock moves that dominated much of January and February:</p><blockquote><i><b>\"From a traditional perspective, the market is fractured and possibly in the process of breaking completely.\"</b></i></blockquote><p>Einhorn's full letter is below:</p><p><img src=\"https://static.tigerbbs.com/519bd51d93865787f487bbfdc930c706\" tg-width=\"946\" tg-height=\"496\"><img src=\"https://static.tigerbbs.com/1691d37b71b28794a2bc900aaf5b313e\" tg-width=\"857\" tg-height=\"687\"><img src=\"https://static.tigerbbs.com/a5d1e93a00a6d64936e9c09b9b940dbf\" tg-width=\"891\" tg-height=\"719\"><img src=\"https://static.tigerbbs.com/0c11ad8e34545a98ba8ee9c4fa8a78d9\" tg-width=\"909\" tg-height=\"477\"><img src=\"https://static.tigerbbs.com/fc8253cd105c8e2727495e1d34c6769b\" tg-width=\"887\" tg-height=\"719\"><img src=\"https://static.tigerbbs.com/e120ac355802479930a1b1e84bf46e3e\" tg-width=\"901\" tg-height=\"528\"><img src=\"https://static.tigerbbs.com/28989c8e07df2deede3e092055e09e70\" tg-width=\"895\" tg-height=\"564\"><img src=\"https://static.tigerbbs.com/7d526b287d859e129d81853c0be2ace0\" tg-width=\"869\" tg-height=\"559\"><img src=\"https://static.tigerbbs.com/8599ce79c9573aed1ca3b1266bd3400a\" tg-width=\"871\" tg-height=\"534\"><img src=\"https://static.tigerbbs.com/3ae554a242066a92e4095f35260ce325\" tg-width=\"917\" tg-height=\"639\"><img src=\"https://static.tigerbbs.com/df45fd1c31a9a0b5a376ec0fe6037598\" tg-width=\"883\" tg-height=\"522\"><img src=\"https://static.tigerbbs.com/b72d0f63d22768ed27882dca1e9f6048\" tg-width=\"878\" tg-height=\"420\"><img src=\"https://static.tigerbbs.com/cf93a682ea1bc652b5107e7ecf902b84\" tg-width=\"862\" tg-height=\"456\"><img src=\"https://static.tigerbbs.com/f0326abf9ee7f93425e7d4cb20e1f375\" tg-width=\"900\" tg-height=\"657\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Einhorn: \"The Market Is Fractured And In The Process Of Breaking Completely\"</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEinhorn: \"The Market Is Fractured And In The Process Of Breaking Completely\"\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 16:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/einhorn-market-fractured-and-process-breaking-completely><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In many ways, David Einhorn's Greenlight appears to be back to its \"new normal\" - in a letter sent to investors, Einhorn writes that Greenlight again underperformed the market and returned -0.1% in ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/einhorn-market-fractured-and-process-breaking-completely\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯","SPY":"标普500ETF",".IXIC":"NASDAQ Composite"},"source_url":"https://www.zerohedge.com/markets/einhorn-market-fractured-and-process-breaking-completely","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156411249","content_text":"In many ways, David Einhorn's Greenlight appears to be back to its \"new normal\" - in a letter sent to investors, Einhorn writes that Greenlight again underperformed the market and returned -0.1% in the first quarter, badly underperforming the 6.2% return for the S&P 500 index, before proceeding to bash the Fed, broken markets, Chamath and Elon, the basket of short stocks and much more.That said, even though as Einhorn writes Greenlight made only a handful of portfolio changes and essentially broke even, \"a lot happened. In general, the investment environment – especially from mid-February through the end of the quarter – was favorable as value outperformed growth, and interest rates and inflation expectations rose.\"He then asks if the tide hasfinallyturned from Growth to Value, noting that \"after a very tough decade, we have only just begun a recovery as shown in this 45-year chart from Goldman Sachs research:\"Part of the shift from growth to value, Einhorn writes, may be coming from higher inflation and inflation expectations. As measured by the inflation swap market, 10-year inflation expectations fell from 2.9% in September 2012 to 0.8% in March 2020. The only significant intervening bounce came in 2016, when expectations jumped from 1.5% to 2.3% on expectations of a major stimulus deal from the Trump admin (which never materialized). It is hardly a coincidence that that was the only year in the last decade in which value outperformed growth, as the Greenlight head notes. Fast forward to now, when after bottoming in March 2020, inflation expectations have recovered to 2.5%. The trend became clearer in the middle of May, and value started outperforming growth then, and especially since the middle of February. Indeed, aince May 15, the value-heavy Greenlight returned 80% of the S&P 500 index with half the net exposure.Einhorn is even more optimistic about the future when it comes to the \"growth to value\" rotation:When the time comes, we will have to figure out how to perform better in deflationary periods. But for now, we believe inflation is only going one way – higher – and we are optimistic about our prospects. The wind is now at our backs. The economy is in full recovery mode. Household balance sheets are stronger than they have been in a long time and household income growth was up 13% in February compared to last year. And this is before the latest $1.9 trillion – with a “T” – pandemic relief stimulus. Corporate capital spending is booming. There are shortages and bottlenecks everywhere. Last month nearly one million jobs returned. There are signs of an emerging labor shortage.As for the Fed, the Greenlight boss writes that \"it fundamentally changed its framework last August. It no longer seems to care that monetary policy works with a lag. Actually, it has embraced an asymmetrical inflation policy: The Fed wants to be ahead of the curve on the downside to protectthe stock market and corporate bondholdersthe economy. Behind the curve is fine on the way up no matter how frothy the stock market the recovery is. Now, it says it is only going to react to actual inflation that exceeds its 2% target for a period of time.\"The letter then goes on to muse how the Fed will know when it is blowing the next bubble, and to stop:... the Fed has indicated that it believes any abnormally high inflation will be transitory. We wonder, how will the Fed know? Do price increases come with a label that says “transitory”? Our sense is that no matter how hot inflation gets in the coming months, the Fed will continue with zero interest rates and large-scale asset purchases. After all, the U.S. Treasury has a lot of debt to sell and it isn’t clear who, other than the Fed, can absorb the supply.It's not just Powell who is throwing caution to the wind: so are such mainstream econ \"experts\" as John Oliver:The bipartisan idea that deficits don’t matter has even reached popular culture. John Oliverdedicated an entire episodeof Last Week Tonight to browbeating anyone who is concerned about the growing national debt. His argument boiled down to: (1) nobody knows how much debt is too much; (2) we have a good need to spend money now; and (3) it won’t be a problem until inflation shows up, and we can deal with it then.To this, Einhorn's response is simple: \"Though one can debate whether the official government statistics are contrived to avoid capturing inflation\" - and as we have repeatedly noted, inflation is now decidedly a political measurement, one which has been gamed for decades to make it appears as low as possible \"shortages and bottlenecks accompanied by rising demand can only be solved through increased capacity and higher prices. We have also reset the baseline income for non-working adults; it will take higher wages to bring those marginally attached to the labor force back to work.\"Concluding this part of the letter, Einhorn writes that while the Fed says it has the tools to fight inflation (and according to Bernanke can cut it in15 minutes), \"it remains to be seen if it will have the stomach to use them when the time comes. Thatis a discussion for another day. Right now, we remain positioned for rising inflation and inflation expectations.\"The Greenlight letter then goes on to lay out just how it plans to capture these rising inflation expectations, listing its top positions as follows, and how they performed in the frist quarter:Brighthouse Financial (BHF, +22%)benefitted from rising interest rates;Danimer Scientific (DNMR, +61%)began its life as a public company;Concentrix (CNXC, +52%)benefitted from strong demand and rising estimates;Resideo Technologies (REZI, +33%)was helped by the strong housing market;Change Healthcare (CHNG, +18%)agreed to be acquired by UnitedHealthcare;AerCap Holdings (AER, +29%)agreed to acquire GE Capital’s aircraft leasing business (GECAS) at a discount; andAn undisclosed healthcare short (-41%)fell due to reduced government reimbursement for its product.(incidentally, at quarter-end, Greenlight's largest disclosed long positions were Atlas Air Worldwide, Brighthouse Financial, Change Healthcare, Danimer Scientific and Green Brick Partners, with a net average exposure of 118% long and 81% short).Which is not to say that there were no glitches. One was underperformance by homebuilder and land-developer GRBK, the fund's largest position (more on this in the full letter below). The other performance drag was - as usual- Greenlight's \"short basket\" of bubble stocks.What follows next is a tour de force from Einhorn lashing out at all the ways the market is broken, and how the Reddit insanity of Q1 exposed it for all to see:In late January, the market came to focus on companies with large short interests. Despite having a diversified portfolio, a number of our positions fell into this group and experienced sudden, sharp rises. We adjusted to the dynamic by reducing our exposure to single name shorts, both in number and sizing. To mitigate the potentially uncomfortable net long bias that would have resulted, we added macro hedges of market index and index option shorts. While we do not expect this to be a permanent change, we will evaluate and modify as we go. The performance of our short portfolio in 2020 and in early 2021 was unacceptable, so change is certainly needed. If we swing a little less hard, we should hit more balls. We have also revised our internal analyst incentive structure to fully emphasize alpha creation.Much has been made of the short-squeezes in late January. In fact, Congress held hearings, where it called the leaders of Robinhood, Melvin Capital and Citadel and an individual investor who made a great call on GameStop (GME) to testify. We have a few thoughts about this to share. First, it is very healthy for market participants to discuss and debate stocks. This is true both privately and publicly. There are rules about fraud and manipulation that need to be followed, but investors discussing why they think GME (or any other stock) should go up or down ought to be encouraged. There is no reason to drag anyone before Congress for making a stock pick. Second, it is also fine to make bad stock picks. If a hedge fund takes a big position in a stock and is wrong, it loses money. Isn’t this how it is supposed to work? Third, payment for order flow is just disguised commissions. We are in a world where consumers, especially young ones, expect internet services to be free, or at least free to them. A quote widely attributed to Richard Serra about commercial TV in 1973 says it best: “You’re not the customer; you’re the product.” If you want the broker to work for you, pay a commission. Fourth, Robinhood suspended trading in certain stocks because it was undercapitalized. It is possible that it wasn’t following the regulatory requirements. A regulatory sanction is probably appropriate – but as we’ll discuss below, we won’t be holding our breath.The punchline:Einhorn slamming Chamath and Elon for pouring the \"real jet fuel\" on the GME squeeze:Finally, we note that the real jet fuel on the GME squeeze came from Chamath Palihapitiya and Elon Musk, whose appearances on TV and Twitter, respectively, at a critical moment further destabilized the situation. Mr. Palihapitiya controls SoFi, which competes with Robinhood, and left us with the impression that by destabilizing GME he could harm a competitor. As for Mr. Musk, we are going to defend him, half-heartedly. If regulators wanted Elon Musk to stop manipulating stocks, they should have done so with more than a light slap on the wrist when they accused him of manipulating Tesla’s shares in 2018. The laws don’t apply to him and he can do whatever he wants. Many who would never support defunding the police have supported – and for all intents and purposes have succeeded – in almost completely defanging, if not defunding, the regulators. For the most part, quasi-anarchy appears to rule in markets. Sure, Dr. Michael Burry, famed for his role in The Big Short, reportedly received a visit from the SEC after tweeting warnings about recent market trends – and decided to stop publicly speaking truth to power. But for the most part, there is no cop on the beat. It’s as if there are no financial fraud prosecutors; companies and managements that are emboldened enough to engage in malfeasance have little to fear.Einhorn then concludes with three anecdotes to demonstrate his argument that this is not only an \"anything goes\" market where crime is rampant, but proving just how broken the market has become.First, consider the investigation of Tether by the Office of the Attorney General of New York (OAG). As Einhorn explains, \"tether is a cryptocurrency that is always worth a dollar (the value is “tethered” to the dollar). Tether is one of the largest cryptocurrencies with about $40 billion outstanding, yet it has not been audited or regulated in any serious manner. In theory, Tether is supposed to have $1 of cash backing every Tether issued. Except it didn’t, at least when it was investigated.\" Incidentally, for anyone still confused, Tether is how theChinese launder billions in domestic funds abroad and outside the Chinese firewallas we explained in December, although so far few have the desire to expose this reality. In any case, here is Einhorn's lament:The OAG conducted a two-year probe and found that Tether deceived clients and the market by overstating reserves and hiding approximately $850 million of losses around the globe. Tether and its sponsor, Bitfinex, “recklessly and unlawfully covered up massive financial losses to keep their scheme going and protect their bottom lines,” said the OAG. Further, “Tether’s claims that its virtual currency was fully backed by U.S. dollars at all times was a lie.”Did the OAG shut down Tether? Did anyone get arrested or even lose their job? Was the regulatory infrastructure changed to make sure this doesn’t happen again? No, of course not. The OAG assessed an $18.5 million penalty and Tether agreed to discontinue “any trading activity with New Yorkers.” It was as if Bernie Madoff had been told to pay a small fine and stop ripping off New Yorkers, but to go ahead and have fun with the Palm Beach crowd.Einhorn next highlights one of the stocks most hated by the bearish community: GSX:The media is focused on how the banks allowed excessive leverage and poorly (or properly) managed their risks. The real story is how Arch-Egos was able to buy up most of the float of GSX Techedu, causing the stock to soar 400% in the face of unrefuted allegations of massive fraud.The SEC has an ongoing investigation of GSX but appears to not have noticed a single fund (or a small group of funds) essentially cornering the market. A traditionalist could say this was market manipulation and transparently illegal.The professional poker player finally points out some of the insane moves observed in pennystocks in Q1, focusing on a tiny deli owner in rural NJ:Strange things happen to all kinds of stocks. Last year, on one day in June, the stocks of about a dozen bankrupt companies roughly doubled on enormous volume. Recently, the Wall Street Journal reported a boom in penny stocks.Someone pointed us to Hometown International (HWIN), which owns a single deli in rural New Jersey. The deli had $21,772 in sales in 2019 and only $13,976 in 2020, as it was closed due to COVID from March to September. HWIN reached a market cap of $113 million on February 8. The largest shareholder is also the CEO/CFO/Treasurer and a Director, who also happens to be the wrestling coach of the high school next door to the deli. The pastrami must be amazing. Small investors who get sucked into these situations are likely to be harmed eventually, yet the regulators – who are supposed to be protecting investors – appear to be neither present nor curious.We don't find it at all surprising that Einhorn's conclusion from his capital markets observations over the past quarter isidenticalto ours, when we discussed the insane stock moves that dominated much of January and February:\"From a traditional perspective, the market is fractured and possibly in the process of breaking completely.\"Einhorn's full letter is below:","news_type":1},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379992711,"gmtCreate":1618648961133,"gmtModify":1704713821136,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379992711","repostId":"2127834845","repostType":4,"repost":{"id":"2127834845","kind":"highlight","pubTimestamp":1618573920,"share":"https://ttm.financial/m/news/2127834845?lang=&edition=fundamental","pubTime":"2021-04-16 19:52","market":"us","language":"en","title":"The Smartest Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2127834845","media":"Motley Fool","summary":"It's easy to build wealth on Wall Street when you own stakes in great businesses.","content":"<p>For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.</p>\n<p>The reason? Over time, operating earnings growth drives equity valuations higher. We're never going to be able to predict what happens in the short run with any accuracy, but buying game-changing businesses and holding onto them for long periods of time tends to be a surefire moneymaking strategy.</p>\n<p>But here's what most folks overlook: You don't need a gigantic pocketbook to build wealth on Wall Street. If you have $200 you can spare, which won't be needed to pay bills or cover an emergency, you have more than enough to start or further your trek toward financial independence. Here are some of the smartest stocks you can buy right now with $200.</p>\n<p><img src=\"https://static.tigerbbs.com/5876cf8596571681f0d3218da4f74c8c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Palantir Technologies</h2>\n<p>One of the best ways for patient investors to put $200 to work right now would be to buy data-mining specialist <b>Palantir Technologies</b> (NYSE:PLTR). The company isn't exactly cheap at 42 times last year's sales but it's growing so quickly that it has a good chance to grow into its big shoes, so to speak.</p>\n<p>Palantir is a dual-threat company. Its Gotham platform is designed to help the U.S. government mine through copious amounts of data so it can plan missions and keep its citizens safe. Multiple branches of the U.S. government have existing or pending contracts with the company. In total, 56% of its roughly $1.1 billion in sales last year were brought in by Gotham.</p>\n<p>There's also the company's Foundry platform, which provides large-scale data analytics for predominantly medium- and large-sized businesses. Without getting too deep into company speak, Foundry allows businesses to aggregate and visualize their data to better streamline their operations. Foundry ended 2020 with 24 customers in the Global 300, implying it has a long runway to land new clients.</p>\n<p>What both Gotham and Foundry bring to the table is a reliance on artificial intelligence (AI). Palantir's software solutions lean on AI to grow smarter all the time. Being able to adapt to a dynamic world and economy is what's helped Palantir hang onto its biggest clients.</p>\n<p>What should investors expect from Palantir? Look for bigger businesses to latch on, but at the same time, the company's concentration of sales from its biggest customers may decline. By mid-decade, Foundry has the potential to be Palantir's core growth driver. Sales growth could reasonably remain in the 30%+ range for much of the decade.</p>\n<p><img src=\"https://static.tigerbbs.com/80c225697d010d56dce760fb7f02e537\" tg-width=\"700\" tg-height=\"525\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Cresco Labs</h2>\n<p>Another exceptionally smart way to put $200 to work right now is by focusing on U.S. marijuana stocks. Even though Canadian pot stocks are more well-known, it's the U.S. multistate operators (MSO) that have a clear path to fast double-digit growth rates and recurring profitability. The cannabis stock that looks particularly cheap at the moment is <b>Cresco Labs</b> (OTC:CRLBF).</p>\n<p>Not to sound like a broken record, but Cresco Labs is also a dual threat. On <a href=\"https://laohu8.com/S/AONE\">one</a> hand, it has its retail segment, which is common for pretty much all MSOs. Not including two pending acquisitions, Cresco has 24 operational dispensaries at the moment, with 29 total licenses in its back pocket. If the aforementioned deals close, it'll have more than 30 open dispensaries and the ability to have close to four dozen retail stores.</p>\n<p>Perhaps the most interesting thing about Cresco's retail approach is that it's targeting a handful of limited-license markets. It's maximized its presence in Illinois (10 stores) and Ohio (5 stores), each of which caps the number of retail stores allowable in their respective states. By focusing on these limited-license markets, Cresco is giving itself the best possible chance to scoop up market share in billion-dollar markets.</p>\n<p>On the other hand, Cresco has the cannabis industry's leading wholesale operations, which accounted for just over half of its 2020 sales. Wall Street appears to be discounting Cresco Labs relative to its peers because wholesale produces lower margins than retail. The thing is, Cresco's wholesale segment has access to more than 575 dispensaries in California, the largest marijuana market in the world by annual sales.</p>\n<p>Investors can currently scoop up shares of Cresco for about 2.5 times forward-year sales, which is well below the industry average for U.S. MSOs. That's a big-time bargain folks shouldn't pass up.</p>\n<p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Bristol Myers Squibb</h2>\n<p>For those of you who aren't big risk takers, consider putting your $200 to work in pharmaceutical stock <b>Bristol Myers Squibb</b> (NYSE:BMY). Would you be surprised if I mentioned that Bristol Myers is a dual threat, with both acquisitive and organic growth driving its top and bottom line higher?</p>\n<p>On the acquisition front, Bristol Myers completed its purchase of drug developer Celgene in November 2019. Celgene primarily focused its efforts in oncology and immunology, with multiple myeloma superstar Revlimid leading the way.</p>\n<p>Since its approval by the U.S. Food and Drug Administration (FDA) more than a decade ago, Revlimid has been growing annually by a double-digit percentage. It has benefited from label-expansion opportunities, longer duration of use, improved cancer-screening diagnostics, and strong pricing power.</p>\n<p>Last year, Revlimid bought in $12.1 billion of Bristol Myers' $42.5 billion in worldwide product sales. The best part is it's protected from a full onslaught of generic competition until the end of January 2026. This gives Bristol Myers Squibb almost five more years to rake in the cash flow from this blockbuster.</p>\n<p>On the organic-growth front, all eyes are on blood thinner Eliquis, which was co-developed with <b>Pfizer</b>, and cancer immunotherapy Opdivo. Eliquis has become the leading global oral anticoagulant, with Bristol Myers recognizing nearly $9.2 billion in sales in 2020 (up 16%). Meanwhile, Opdivo's sales retraced slightly to $7 billion last year. Nevertheless, Opdivo is being examined in dozens of clinical trials as a monotherapy or combination therapy, which offers plenty of hope for future label-expansion opportunities.</p>\n<p>The bottom line is that investors can buy shares of Bristol Myers Squibb for about eight times Wall Street's forward-year consensus earnings, which is downright cheap. They'll also net a cool 3.1% dividend yield for their patience.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 19:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.\nThe reason? Over time,...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127834845","content_text":"For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.\nThe reason? Over time, operating earnings growth drives equity valuations higher. We're never going to be able to predict what happens in the short run with any accuracy, but buying game-changing businesses and holding onto them for long periods of time tends to be a surefire moneymaking strategy.\nBut here's what most folks overlook: You don't need a gigantic pocketbook to build wealth on Wall Street. If you have $200 you can spare, which won't be needed to pay bills or cover an emergency, you have more than enough to start or further your trek toward financial independence. Here are some of the smartest stocks you can buy right now with $200.\n\nImage source: Getty Images.\nPalantir Technologies\nOne of the best ways for patient investors to put $200 to work right now would be to buy data-mining specialist Palantir Technologies (NYSE:PLTR). The company isn't exactly cheap at 42 times last year's sales but it's growing so quickly that it has a good chance to grow into its big shoes, so to speak.\nPalantir is a dual-threat company. Its Gotham platform is designed to help the U.S. government mine through copious amounts of data so it can plan missions and keep its citizens safe. Multiple branches of the U.S. government have existing or pending contracts with the company. In total, 56% of its roughly $1.1 billion in sales last year were brought in by Gotham.\nThere's also the company's Foundry platform, which provides large-scale data analytics for predominantly medium- and large-sized businesses. Without getting too deep into company speak, Foundry allows businesses to aggregate and visualize their data to better streamline their operations. Foundry ended 2020 with 24 customers in the Global 300, implying it has a long runway to land new clients.\nWhat both Gotham and Foundry bring to the table is a reliance on artificial intelligence (AI). Palantir's software solutions lean on AI to grow smarter all the time. Being able to adapt to a dynamic world and economy is what's helped Palantir hang onto its biggest clients.\nWhat should investors expect from Palantir? Look for bigger businesses to latch on, but at the same time, the company's concentration of sales from its biggest customers may decline. By mid-decade, Foundry has the potential to be Palantir's core growth driver. Sales growth could reasonably remain in the 30%+ range for much of the decade.\n\nImage source: Getty Images.\nCresco Labs\nAnother exceptionally smart way to put $200 to work right now is by focusing on U.S. marijuana stocks. Even though Canadian pot stocks are more well-known, it's the U.S. multistate operators (MSO) that have a clear path to fast double-digit growth rates and recurring profitability. The cannabis stock that looks particularly cheap at the moment is Cresco Labs (OTC:CRLBF).\nNot to sound like a broken record, but Cresco Labs is also a dual threat. On one hand, it has its retail segment, which is common for pretty much all MSOs. Not including two pending acquisitions, Cresco has 24 operational dispensaries at the moment, with 29 total licenses in its back pocket. If the aforementioned deals close, it'll have more than 30 open dispensaries and the ability to have close to four dozen retail stores.\nPerhaps the most interesting thing about Cresco's retail approach is that it's targeting a handful of limited-license markets. It's maximized its presence in Illinois (10 stores) and Ohio (5 stores), each of which caps the number of retail stores allowable in their respective states. By focusing on these limited-license markets, Cresco is giving itself the best possible chance to scoop up market share in billion-dollar markets.\nOn the other hand, Cresco has the cannabis industry's leading wholesale operations, which accounted for just over half of its 2020 sales. Wall Street appears to be discounting Cresco Labs relative to its peers because wholesale produces lower margins than retail. The thing is, Cresco's wholesale segment has access to more than 575 dispensaries in California, the largest marijuana market in the world by annual sales.\nInvestors can currently scoop up shares of Cresco for about 2.5 times forward-year sales, which is well below the industry average for U.S. MSOs. That's a big-time bargain folks shouldn't pass up.\n\nImage source: Getty Images.\nBristol Myers Squibb\nFor those of you who aren't big risk takers, consider putting your $200 to work in pharmaceutical stock Bristol Myers Squibb (NYSE:BMY). Would you be surprised if I mentioned that Bristol Myers is a dual threat, with both acquisitive and organic growth driving its top and bottom line higher?\nOn the acquisition front, Bristol Myers completed its purchase of drug developer Celgene in November 2019. Celgene primarily focused its efforts in oncology and immunology, with multiple myeloma superstar Revlimid leading the way.\nSince its approval by the U.S. Food and Drug Administration (FDA) more than a decade ago, Revlimid has been growing annually by a double-digit percentage. It has benefited from label-expansion opportunities, longer duration of use, improved cancer-screening diagnostics, and strong pricing power.\nLast year, Revlimid bought in $12.1 billion of Bristol Myers' $42.5 billion in worldwide product sales. The best part is it's protected from a full onslaught of generic competition until the end of January 2026. This gives Bristol Myers Squibb almost five more years to rake in the cash flow from this blockbuster.\nOn the organic-growth front, all eyes are on blood thinner Eliquis, which was co-developed with Pfizer, and cancer immunotherapy Opdivo. Eliquis has become the leading global oral anticoagulant, with Bristol Myers recognizing nearly $9.2 billion in sales in 2020 (up 16%). Meanwhile, Opdivo's sales retraced slightly to $7 billion last year. Nevertheless, Opdivo is being examined in dozens of clinical trials as a monotherapy or combination therapy, which offers plenty of hope for future label-expansion opportunities.\nThe bottom line is that investors can buy shares of Bristol Myers Squibb for about eight times Wall Street's forward-year consensus earnings, which is downright cheap. They'll also net a cool 3.1% dividend yield for their patience.","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379996487,"gmtCreate":1618648833649,"gmtModify":1704713819507,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379996487","repostId":"2127834845","repostType":4,"repost":{"id":"2127834845","kind":"highlight","pubTimestamp":1618573920,"share":"https://ttm.financial/m/news/2127834845?lang=&edition=fundamental","pubTime":"2021-04-16 19:52","market":"us","language":"en","title":"The Smartest Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2127834845","media":"Motley Fool","summary":"It's easy to build wealth on Wall Street when you own stakes in great businesses.","content":"<p>For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.</p>\n<p>The reason? Over time, operating earnings growth drives equity valuations higher. We're never going to be able to predict what happens in the short run with any accuracy, but buying game-changing businesses and holding onto them for long periods of time tends to be a surefire moneymaking strategy.</p>\n<p>But here's what most folks overlook: You don't need a gigantic pocketbook to build wealth on Wall Street. If you have $200 you can spare, which won't be needed to pay bills or cover an emergency, you have more than enough to start or further your trek toward financial independence. Here are some of the smartest stocks you can buy right now with $200.</p>\n<p><img src=\"https://static.tigerbbs.com/5876cf8596571681f0d3218da4f74c8c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Palantir Technologies</h2>\n<p>One of the best ways for patient investors to put $200 to work right now would be to buy data-mining specialist <b>Palantir Technologies</b> (NYSE:PLTR). The company isn't exactly cheap at 42 times last year's sales but it's growing so quickly that it has a good chance to grow into its big shoes, so to speak.</p>\n<p>Palantir is a dual-threat company. Its Gotham platform is designed to help the U.S. government mine through copious amounts of data so it can plan missions and keep its citizens safe. Multiple branches of the U.S. government have existing or pending contracts with the company. In total, 56% of its roughly $1.1 billion in sales last year were brought in by Gotham.</p>\n<p>There's also the company's Foundry platform, which provides large-scale data analytics for predominantly medium- and large-sized businesses. Without getting too deep into company speak, Foundry allows businesses to aggregate and visualize their data to better streamline their operations. Foundry ended 2020 with 24 customers in the Global 300, implying it has a long runway to land new clients.</p>\n<p>What both Gotham and Foundry bring to the table is a reliance on artificial intelligence (AI). Palantir's software solutions lean on AI to grow smarter all the time. Being able to adapt to a dynamic world and economy is what's helped Palantir hang onto its biggest clients.</p>\n<p>What should investors expect from Palantir? Look for bigger businesses to latch on, but at the same time, the company's concentration of sales from its biggest customers may decline. By mid-decade, Foundry has the potential to be Palantir's core growth driver. Sales growth could reasonably remain in the 30%+ range for much of the decade.</p>\n<p><img src=\"https://static.tigerbbs.com/80c225697d010d56dce760fb7f02e537\" tg-width=\"700\" tg-height=\"525\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Cresco Labs</h2>\n<p>Another exceptionally smart way to put $200 to work right now is by focusing on U.S. marijuana stocks. Even though Canadian pot stocks are more well-known, it's the U.S. multistate operators (MSO) that have a clear path to fast double-digit growth rates and recurring profitability. The cannabis stock that looks particularly cheap at the moment is <b>Cresco Labs</b> (OTC:CRLBF).</p>\n<p>Not to sound like a broken record, but Cresco Labs is also a dual threat. On <a href=\"https://laohu8.com/S/AONE\">one</a> hand, it has its retail segment, which is common for pretty much all MSOs. Not including two pending acquisitions, Cresco has 24 operational dispensaries at the moment, with 29 total licenses in its back pocket. If the aforementioned deals close, it'll have more than 30 open dispensaries and the ability to have close to four dozen retail stores.</p>\n<p>Perhaps the most interesting thing about Cresco's retail approach is that it's targeting a handful of limited-license markets. It's maximized its presence in Illinois (10 stores) and Ohio (5 stores), each of which caps the number of retail stores allowable in their respective states. By focusing on these limited-license markets, Cresco is giving itself the best possible chance to scoop up market share in billion-dollar markets.</p>\n<p>On the other hand, Cresco has the cannabis industry's leading wholesale operations, which accounted for just over half of its 2020 sales. Wall Street appears to be discounting Cresco Labs relative to its peers because wholesale produces lower margins than retail. The thing is, Cresco's wholesale segment has access to more than 575 dispensaries in California, the largest marijuana market in the world by annual sales.</p>\n<p>Investors can currently scoop up shares of Cresco for about 2.5 times forward-year sales, which is well below the industry average for U.S. MSOs. That's a big-time bargain folks shouldn't pass up.</p>\n<p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Bristol Myers Squibb</h2>\n<p>For those of you who aren't big risk takers, consider putting your $200 to work in pharmaceutical stock <b>Bristol Myers Squibb</b> (NYSE:BMY). Would you be surprised if I mentioned that Bristol Myers is a dual threat, with both acquisitive and organic growth driving its top and bottom line higher?</p>\n<p>On the acquisition front, Bristol Myers completed its purchase of drug developer Celgene in November 2019. Celgene primarily focused its efforts in oncology and immunology, with multiple myeloma superstar Revlimid leading the way.</p>\n<p>Since its approval by the U.S. Food and Drug Administration (FDA) more than a decade ago, Revlimid has been growing annually by a double-digit percentage. It has benefited from label-expansion opportunities, longer duration of use, improved cancer-screening diagnostics, and strong pricing power.</p>\n<p>Last year, Revlimid bought in $12.1 billion of Bristol Myers' $42.5 billion in worldwide product sales. The best part is it's protected from a full onslaught of generic competition until the end of January 2026. This gives Bristol Myers Squibb almost five more years to rake in the cash flow from this blockbuster.</p>\n<p>On the organic-growth front, all eyes are on blood thinner Eliquis, which was co-developed with <b>Pfizer</b>, and cancer immunotherapy Opdivo. Eliquis has become the leading global oral anticoagulant, with Bristol Myers recognizing nearly $9.2 billion in sales in 2020 (up 16%). Meanwhile, Opdivo's sales retraced slightly to $7 billion last year. Nevertheless, Opdivo is being examined in dozens of clinical trials as a monotherapy or combination therapy, which offers plenty of hope for future label-expansion opportunities.</p>\n<p>The bottom line is that investors can buy shares of Bristol Myers Squibb for about eight times Wall Street's forward-year consensus earnings, which is downright cheap. They'll also net a cool 3.1% dividend yield for their patience.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 19:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.\nThe reason? Over time,...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127834845","content_text":"For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.\nThe reason? Over time, operating earnings growth drives equity valuations higher. We're never going to be able to predict what happens in the short run with any accuracy, but buying game-changing businesses and holding onto them for long periods of time tends to be a surefire moneymaking strategy.\nBut here's what most folks overlook: You don't need a gigantic pocketbook to build wealth on Wall Street. If you have $200 you can spare, which won't be needed to pay bills or cover an emergency, you have more than enough to start or further your trek toward financial independence. Here are some of the smartest stocks you can buy right now with $200.\n\nImage source: Getty Images.\nPalantir Technologies\nOne of the best ways for patient investors to put $200 to work right now would be to buy data-mining specialist Palantir Technologies (NYSE:PLTR). The company isn't exactly cheap at 42 times last year's sales but it's growing so quickly that it has a good chance to grow into its big shoes, so to speak.\nPalantir is a dual-threat company. Its Gotham platform is designed to help the U.S. government mine through copious amounts of data so it can plan missions and keep its citizens safe. Multiple branches of the U.S. government have existing or pending contracts with the company. In total, 56% of its roughly $1.1 billion in sales last year were brought in by Gotham.\nThere's also the company's Foundry platform, which provides large-scale data analytics for predominantly medium- and large-sized businesses. Without getting too deep into company speak, Foundry allows businesses to aggregate and visualize their data to better streamline their operations. Foundry ended 2020 with 24 customers in the Global 300, implying it has a long runway to land new clients.\nWhat both Gotham and Foundry bring to the table is a reliance on artificial intelligence (AI). Palantir's software solutions lean on AI to grow smarter all the time. Being able to adapt to a dynamic world and economy is what's helped Palantir hang onto its biggest clients.\nWhat should investors expect from Palantir? Look for bigger businesses to latch on, but at the same time, the company's concentration of sales from its biggest customers may decline. By mid-decade, Foundry has the potential to be Palantir's core growth driver. Sales growth could reasonably remain in the 30%+ range for much of the decade.\n\nImage source: Getty Images.\nCresco Labs\nAnother exceptionally smart way to put $200 to work right now is by focusing on U.S. marijuana stocks. Even though Canadian pot stocks are more well-known, it's the U.S. multistate operators (MSO) that have a clear path to fast double-digit growth rates and recurring profitability. The cannabis stock that looks particularly cheap at the moment is Cresco Labs (OTC:CRLBF).\nNot to sound like a broken record, but Cresco Labs is also a dual threat. On one hand, it has its retail segment, which is common for pretty much all MSOs. Not including two pending acquisitions, Cresco has 24 operational dispensaries at the moment, with 29 total licenses in its back pocket. If the aforementioned deals close, it'll have more than 30 open dispensaries and the ability to have close to four dozen retail stores.\nPerhaps the most interesting thing about Cresco's retail approach is that it's targeting a handful of limited-license markets. It's maximized its presence in Illinois (10 stores) and Ohio (5 stores), each of which caps the number of retail stores allowable in their respective states. By focusing on these limited-license markets, Cresco is giving itself the best possible chance to scoop up market share in billion-dollar markets.\nOn the other hand, Cresco has the cannabis industry's leading wholesale operations, which accounted for just over half of its 2020 sales. Wall Street appears to be discounting Cresco Labs relative to its peers because wholesale produces lower margins than retail. The thing is, Cresco's wholesale segment has access to more than 575 dispensaries in California, the largest marijuana market in the world by annual sales.\nInvestors can currently scoop up shares of Cresco for about 2.5 times forward-year sales, which is well below the industry average for U.S. MSOs. That's a big-time bargain folks shouldn't pass up.\n\nImage source: Getty Images.\nBristol Myers Squibb\nFor those of you who aren't big risk takers, consider putting your $200 to work in pharmaceutical stock Bristol Myers Squibb (NYSE:BMY). Would you be surprised if I mentioned that Bristol Myers is a dual threat, with both acquisitive and organic growth driving its top and bottom line higher?\nOn the acquisition front, Bristol Myers completed its purchase of drug developer Celgene in November 2019. Celgene primarily focused its efforts in oncology and immunology, with multiple myeloma superstar Revlimid leading the way.\nSince its approval by the U.S. Food and Drug Administration (FDA) more than a decade ago, Revlimid has been growing annually by a double-digit percentage. It has benefited from label-expansion opportunities, longer duration of use, improved cancer-screening diagnostics, and strong pricing power.\nLast year, Revlimid bought in $12.1 billion of Bristol Myers' $42.5 billion in worldwide product sales. The best part is it's protected from a full onslaught of generic competition until the end of January 2026. This gives Bristol Myers Squibb almost five more years to rake in the cash flow from this blockbuster.\nOn the organic-growth front, all eyes are on blood thinner Eliquis, which was co-developed with Pfizer, and cancer immunotherapy Opdivo. Eliquis has become the leading global oral anticoagulant, with Bristol Myers recognizing nearly $9.2 billion in sales in 2020 (up 16%). Meanwhile, Opdivo's sales retraced slightly to $7 billion last year. Nevertheless, Opdivo is being examined in dozens of clinical trials as a monotherapy or combination therapy, which offers plenty of hope for future label-expansion opportunities.\nThe bottom line is that investors can buy shares of Bristol Myers Squibb for about eight times Wall Street's forward-year consensus earnings, which is downright cheap. They'll also net a cool 3.1% dividend yield for their patience.","news_type":1},"isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":167674161,"gmtCreate":1624267978453,"gmtModify":1703831989964,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"?? ??&nbsp;","listText":"?? ??&nbsp;","text":"?? ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/167674161","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1},"isVote":1,"tweetType":1,"viewCount":793,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144027308,"gmtCreate":1626255579104,"gmtModify":1703756436600,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Urm","listText":"Urm","text":"Urm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/144027308","repostId":"1176184294","repostType":4,"isVote":1,"tweetType":1,"viewCount":933,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379994901,"gmtCreate":1618649126403,"gmtModify":1704713823086,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Urm","listText":"Urm","text":"Urm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379994901","repostId":"1156411249","repostType":4,"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088721555,"gmtCreate":1650384858926,"gmtModify":1676534711047,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for chances","listText":"Posting for chances","text":"Posting for chances","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088721555","isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088553009,"gmtCreate":1650368085917,"gmtModify":1676534706244,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"For easter hunt chance","listText":"For easter hunt chance","text":"For easter hunt chance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088553009","isVote":1,"tweetType":1,"viewCount":947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089921783,"gmtCreate":1649946588253,"gmtModify":1676534612985,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089921783","repostId":"9016476123","repostType":1,"repost":{"id":9016476123,"gmtCreate":1649229403658,"gmtModify":1676534474180,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"🏆【GAME】Hunting Eggs for Extra Saving!","htmlText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","listText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","text":"Tiger has prepared some Easter gifts for you, please click here to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","images":[{"img":"https://community-static.tradeup.com/news/15b435c0d10e0e89ad3e06b7bbd04830","width":"2251","height":"1334"},{"img":"https://community-static.tradeup.com/news/ff9640a9df2f24446e07b7a9b658cb4b","width":"1200","height":"630"},{"img":"https://community-static.tradeup.com/news/795038848b7c7b1d7dda27d92b580946","width":"1656","height":"948"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016476123","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379992711,"gmtCreate":1618648961133,"gmtModify":1704713821136,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379992711","repostId":"2127834845","repostType":4,"repost":{"id":"2127834845","kind":"highlight","pubTimestamp":1618573920,"share":"https://ttm.financial/m/news/2127834845?lang=&edition=fundamental","pubTime":"2021-04-16 19:52","market":"us","language":"en","title":"The Smartest Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2127834845","media":"Motley Fool","summary":"It's easy to build wealth on Wall Street when you own stakes in great businesses.","content":"<p>For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.</p>\n<p>The reason? Over time, operating earnings growth drives equity valuations higher. We're never going to be able to predict what happens in the short run with any accuracy, but buying game-changing businesses and holding onto them for long periods of time tends to be a surefire moneymaking strategy.</p>\n<p>But here's what most folks overlook: You don't need a gigantic pocketbook to build wealth on Wall Street. If you have $200 you can spare, which won't be needed to pay bills or cover an emergency, you have more than enough to start or further your trek toward financial independence. Here are some of the smartest stocks you can buy right now with $200.</p>\n<p><img src=\"https://static.tigerbbs.com/5876cf8596571681f0d3218da4f74c8c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Palantir Technologies</h2>\n<p>One of the best ways for patient investors to put $200 to work right now would be to buy data-mining specialist <b>Palantir Technologies</b> (NYSE:PLTR). The company isn't exactly cheap at 42 times last year's sales but it's growing so quickly that it has a good chance to grow into its big shoes, so to speak.</p>\n<p>Palantir is a dual-threat company. Its Gotham platform is designed to help the U.S. government mine through copious amounts of data so it can plan missions and keep its citizens safe. Multiple branches of the U.S. government have existing or pending contracts with the company. In total, 56% of its roughly $1.1 billion in sales last year were brought in by Gotham.</p>\n<p>There's also the company's Foundry platform, which provides large-scale data analytics for predominantly medium- and large-sized businesses. Without getting too deep into company speak, Foundry allows businesses to aggregate and visualize their data to better streamline their operations. Foundry ended 2020 with 24 customers in the Global 300, implying it has a long runway to land new clients.</p>\n<p>What both Gotham and Foundry bring to the table is a reliance on artificial intelligence (AI). Palantir's software solutions lean on AI to grow smarter all the time. Being able to adapt to a dynamic world and economy is what's helped Palantir hang onto its biggest clients.</p>\n<p>What should investors expect from Palantir? Look for bigger businesses to latch on, but at the same time, the company's concentration of sales from its biggest customers may decline. By mid-decade, Foundry has the potential to be Palantir's core growth driver. Sales growth could reasonably remain in the 30%+ range for much of the decade.</p>\n<p><img src=\"https://static.tigerbbs.com/80c225697d010d56dce760fb7f02e537\" tg-width=\"700\" tg-height=\"525\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Cresco Labs</h2>\n<p>Another exceptionally smart way to put $200 to work right now is by focusing on U.S. marijuana stocks. Even though Canadian pot stocks are more well-known, it's the U.S. multistate operators (MSO) that have a clear path to fast double-digit growth rates and recurring profitability. The cannabis stock that looks particularly cheap at the moment is <b>Cresco Labs</b> (OTC:CRLBF).</p>\n<p>Not to sound like a broken record, but Cresco Labs is also a dual threat. On <a href=\"https://laohu8.com/S/AONE\">one</a> hand, it has its retail segment, which is common for pretty much all MSOs. Not including two pending acquisitions, Cresco has 24 operational dispensaries at the moment, with 29 total licenses in its back pocket. If the aforementioned deals close, it'll have more than 30 open dispensaries and the ability to have close to four dozen retail stores.</p>\n<p>Perhaps the most interesting thing about Cresco's retail approach is that it's targeting a handful of limited-license markets. It's maximized its presence in Illinois (10 stores) and Ohio (5 stores), each of which caps the number of retail stores allowable in their respective states. By focusing on these limited-license markets, Cresco is giving itself the best possible chance to scoop up market share in billion-dollar markets.</p>\n<p>On the other hand, Cresco has the cannabis industry's leading wholesale operations, which accounted for just over half of its 2020 sales. Wall Street appears to be discounting Cresco Labs relative to its peers because wholesale produces lower margins than retail. The thing is, Cresco's wholesale segment has access to more than 575 dispensaries in California, the largest marijuana market in the world by annual sales.</p>\n<p>Investors can currently scoop up shares of Cresco for about 2.5 times forward-year sales, which is well below the industry average for U.S. MSOs. That's a big-time bargain folks shouldn't pass up.</p>\n<p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Bristol Myers Squibb</h2>\n<p>For those of you who aren't big risk takers, consider putting your $200 to work in pharmaceutical stock <b>Bristol Myers Squibb</b> (NYSE:BMY). Would you be surprised if I mentioned that Bristol Myers is a dual threat, with both acquisitive and organic growth driving its top and bottom line higher?</p>\n<p>On the acquisition front, Bristol Myers completed its purchase of drug developer Celgene in November 2019. Celgene primarily focused its efforts in oncology and immunology, with multiple myeloma superstar Revlimid leading the way.</p>\n<p>Since its approval by the U.S. Food and Drug Administration (FDA) more than a decade ago, Revlimid has been growing annually by a double-digit percentage. It has benefited from label-expansion opportunities, longer duration of use, improved cancer-screening diagnostics, and strong pricing power.</p>\n<p>Last year, Revlimid bought in $12.1 billion of Bristol Myers' $42.5 billion in worldwide product sales. The best part is it's protected from a full onslaught of generic competition until the end of January 2026. This gives Bristol Myers Squibb almost five more years to rake in the cash flow from this blockbuster.</p>\n<p>On the organic-growth front, all eyes are on blood thinner Eliquis, which was co-developed with <b>Pfizer</b>, and cancer immunotherapy Opdivo. Eliquis has become the leading global oral anticoagulant, with Bristol Myers recognizing nearly $9.2 billion in sales in 2020 (up 16%). Meanwhile, Opdivo's sales retraced slightly to $7 billion last year. Nevertheless, Opdivo is being examined in dozens of clinical trials as a monotherapy or combination therapy, which offers plenty of hope for future label-expansion opportunities.</p>\n<p>The bottom line is that investors can buy shares of Bristol Myers Squibb for about eight times Wall Street's forward-year consensus earnings, which is downright cheap. They'll also net a cool 3.1% dividend yield for their patience.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 19:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.\nThe reason? Over time,...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127834845","content_text":"For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.\nThe reason? Over time, operating earnings growth drives equity valuations higher. We're never going to be able to predict what happens in the short run with any accuracy, but buying game-changing businesses and holding onto them for long periods of time tends to be a surefire moneymaking strategy.\nBut here's what most folks overlook: You don't need a gigantic pocketbook to build wealth on Wall Street. If you have $200 you can spare, which won't be needed to pay bills or cover an emergency, you have more than enough to start or further your trek toward financial independence. Here are some of the smartest stocks you can buy right now with $200.\n\nImage source: Getty Images.\nPalantir Technologies\nOne of the best ways for patient investors to put $200 to work right now would be to buy data-mining specialist Palantir Technologies (NYSE:PLTR). The company isn't exactly cheap at 42 times last year's sales but it's growing so quickly that it has a good chance to grow into its big shoes, so to speak.\nPalantir is a dual-threat company. Its Gotham platform is designed to help the U.S. government mine through copious amounts of data so it can plan missions and keep its citizens safe. Multiple branches of the U.S. government have existing or pending contracts with the company. In total, 56% of its roughly $1.1 billion in sales last year were brought in by Gotham.\nThere's also the company's Foundry platform, which provides large-scale data analytics for predominantly medium- and large-sized businesses. Without getting too deep into company speak, Foundry allows businesses to aggregate and visualize their data to better streamline their operations. Foundry ended 2020 with 24 customers in the Global 300, implying it has a long runway to land new clients.\nWhat both Gotham and Foundry bring to the table is a reliance on artificial intelligence (AI). Palantir's software solutions lean on AI to grow smarter all the time. Being able to adapt to a dynamic world and economy is what's helped Palantir hang onto its biggest clients.\nWhat should investors expect from Palantir? Look for bigger businesses to latch on, but at the same time, the company's concentration of sales from its biggest customers may decline. By mid-decade, Foundry has the potential to be Palantir's core growth driver. Sales growth could reasonably remain in the 30%+ range for much of the decade.\n\nImage source: Getty Images.\nCresco Labs\nAnother exceptionally smart way to put $200 to work right now is by focusing on U.S. marijuana stocks. Even though Canadian pot stocks are more well-known, it's the U.S. multistate operators (MSO) that have a clear path to fast double-digit growth rates and recurring profitability. The cannabis stock that looks particularly cheap at the moment is Cresco Labs (OTC:CRLBF).\nNot to sound like a broken record, but Cresco Labs is also a dual threat. On one hand, it has its retail segment, which is common for pretty much all MSOs. Not including two pending acquisitions, Cresco has 24 operational dispensaries at the moment, with 29 total licenses in its back pocket. If the aforementioned deals close, it'll have more than 30 open dispensaries and the ability to have close to four dozen retail stores.\nPerhaps the most interesting thing about Cresco's retail approach is that it's targeting a handful of limited-license markets. It's maximized its presence in Illinois (10 stores) and Ohio (5 stores), each of which caps the number of retail stores allowable in their respective states. By focusing on these limited-license markets, Cresco is giving itself the best possible chance to scoop up market share in billion-dollar markets.\nOn the other hand, Cresco has the cannabis industry's leading wholesale operations, which accounted for just over half of its 2020 sales. Wall Street appears to be discounting Cresco Labs relative to its peers because wholesale produces lower margins than retail. The thing is, Cresco's wholesale segment has access to more than 575 dispensaries in California, the largest marijuana market in the world by annual sales.\nInvestors can currently scoop up shares of Cresco for about 2.5 times forward-year sales, which is well below the industry average for U.S. MSOs. That's a big-time bargain folks shouldn't pass up.\n\nImage source: Getty Images.\nBristol Myers Squibb\nFor those of you who aren't big risk takers, consider putting your $200 to work in pharmaceutical stock Bristol Myers Squibb (NYSE:BMY). Would you be surprised if I mentioned that Bristol Myers is a dual threat, with both acquisitive and organic growth driving its top and bottom line higher?\nOn the acquisition front, Bristol Myers completed its purchase of drug developer Celgene in November 2019. Celgene primarily focused its efforts in oncology and immunology, with multiple myeloma superstar Revlimid leading the way.\nSince its approval by the U.S. Food and Drug Administration (FDA) more than a decade ago, Revlimid has been growing annually by a double-digit percentage. It has benefited from label-expansion opportunities, longer duration of use, improved cancer-screening diagnostics, and strong pricing power.\nLast year, Revlimid bought in $12.1 billion of Bristol Myers' $42.5 billion in worldwide product sales. The best part is it's protected from a full onslaught of generic competition until the end of January 2026. This gives Bristol Myers Squibb almost five more years to rake in the cash flow from this blockbuster.\nOn the organic-growth front, all eyes are on blood thinner Eliquis, which was co-developed with Pfizer, and cancer immunotherapy Opdivo. Eliquis has become the leading global oral anticoagulant, with Bristol Myers recognizing nearly $9.2 billion in sales in 2020 (up 16%). Meanwhile, Opdivo's sales retraced slightly to $7 billion last year. Nevertheless, Opdivo is being examined in dozens of clinical trials as a monotherapy or combination therapy, which offers plenty of hope for future label-expansion opportunities.\nThe bottom line is that investors can buy shares of Bristol Myers Squibb for about eight times Wall Street's forward-year consensus earnings, which is downright cheap. They'll also net a cool 3.1% dividend yield for their patience.","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379996487,"gmtCreate":1618648833649,"gmtModify":1704713819507,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379996487","repostId":"2127834845","repostType":4,"repost":{"id":"2127834845","kind":"highlight","pubTimestamp":1618573920,"share":"https://ttm.financial/m/news/2127834845?lang=&edition=fundamental","pubTime":"2021-04-16 19:52","market":"us","language":"en","title":"The Smartest Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2127834845","media":"Motley Fool","summary":"It's easy to build wealth on Wall Street when you own stakes in great businesses.","content":"<p>For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.</p>\n<p>The reason? Over time, operating earnings growth drives equity valuations higher. We're never going to be able to predict what happens in the short run with any accuracy, but buying game-changing businesses and holding onto them for long periods of time tends to be a surefire moneymaking strategy.</p>\n<p>But here's what most folks overlook: You don't need a gigantic pocketbook to build wealth on Wall Street. If you have $200 you can spare, which won't be needed to pay bills or cover an emergency, you have more than enough to start or further your trek toward financial independence. Here are some of the smartest stocks you can buy right now with $200.</p>\n<p><img src=\"https://static.tigerbbs.com/5876cf8596571681f0d3218da4f74c8c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Palantir Technologies</h2>\n<p>One of the best ways for patient investors to put $200 to work right now would be to buy data-mining specialist <b>Palantir Technologies</b> (NYSE:PLTR). The company isn't exactly cheap at 42 times last year's sales but it's growing so quickly that it has a good chance to grow into its big shoes, so to speak.</p>\n<p>Palantir is a dual-threat company. Its Gotham platform is designed to help the U.S. government mine through copious amounts of data so it can plan missions and keep its citizens safe. Multiple branches of the U.S. government have existing or pending contracts with the company. In total, 56% of its roughly $1.1 billion in sales last year were brought in by Gotham.</p>\n<p>There's also the company's Foundry platform, which provides large-scale data analytics for predominantly medium- and large-sized businesses. Without getting too deep into company speak, Foundry allows businesses to aggregate and visualize their data to better streamline their operations. Foundry ended 2020 with 24 customers in the Global 300, implying it has a long runway to land new clients.</p>\n<p>What both Gotham and Foundry bring to the table is a reliance on artificial intelligence (AI). Palantir's software solutions lean on AI to grow smarter all the time. Being able to adapt to a dynamic world and economy is what's helped Palantir hang onto its biggest clients.</p>\n<p>What should investors expect from Palantir? Look for bigger businesses to latch on, but at the same time, the company's concentration of sales from its biggest customers may decline. By mid-decade, Foundry has the potential to be Palantir's core growth driver. Sales growth could reasonably remain in the 30%+ range for much of the decade.</p>\n<p><img src=\"https://static.tigerbbs.com/80c225697d010d56dce760fb7f02e537\" tg-width=\"700\" tg-height=\"525\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Cresco Labs</h2>\n<p>Another exceptionally smart way to put $200 to work right now is by focusing on U.S. marijuana stocks. Even though Canadian pot stocks are more well-known, it's the U.S. multistate operators (MSO) that have a clear path to fast double-digit growth rates and recurring profitability. The cannabis stock that looks particularly cheap at the moment is <b>Cresco Labs</b> (OTC:CRLBF).</p>\n<p>Not to sound like a broken record, but Cresco Labs is also a dual threat. On <a href=\"https://laohu8.com/S/AONE\">one</a> hand, it has its retail segment, which is common for pretty much all MSOs. Not including two pending acquisitions, Cresco has 24 operational dispensaries at the moment, with 29 total licenses in its back pocket. If the aforementioned deals close, it'll have more than 30 open dispensaries and the ability to have close to four dozen retail stores.</p>\n<p>Perhaps the most interesting thing about Cresco's retail approach is that it's targeting a handful of limited-license markets. It's maximized its presence in Illinois (10 stores) and Ohio (5 stores), each of which caps the number of retail stores allowable in their respective states. By focusing on these limited-license markets, Cresco is giving itself the best possible chance to scoop up market share in billion-dollar markets.</p>\n<p>On the other hand, Cresco has the cannabis industry's leading wholesale operations, which accounted for just over half of its 2020 sales. Wall Street appears to be discounting Cresco Labs relative to its peers because wholesale produces lower margins than retail. The thing is, Cresco's wholesale segment has access to more than 575 dispensaries in California, the largest marijuana market in the world by annual sales.</p>\n<p>Investors can currently scoop up shares of Cresco for about 2.5 times forward-year sales, which is well below the industry average for U.S. MSOs. That's a big-time bargain folks shouldn't pass up.</p>\n<p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Bristol Myers Squibb</h2>\n<p>For those of you who aren't big risk takers, consider putting your $200 to work in pharmaceutical stock <b>Bristol Myers Squibb</b> (NYSE:BMY). Would you be surprised if I mentioned that Bristol Myers is a dual threat, with both acquisitive and organic growth driving its top and bottom line higher?</p>\n<p>On the acquisition front, Bristol Myers completed its purchase of drug developer Celgene in November 2019. Celgene primarily focused its efforts in oncology and immunology, with multiple myeloma superstar Revlimid leading the way.</p>\n<p>Since its approval by the U.S. Food and Drug Administration (FDA) more than a decade ago, Revlimid has been growing annually by a double-digit percentage. It has benefited from label-expansion opportunities, longer duration of use, improved cancer-screening diagnostics, and strong pricing power.</p>\n<p>Last year, Revlimid bought in $12.1 billion of Bristol Myers' $42.5 billion in worldwide product sales. The best part is it's protected from a full onslaught of generic competition until the end of January 2026. This gives Bristol Myers Squibb almost five more years to rake in the cash flow from this blockbuster.</p>\n<p>On the organic-growth front, all eyes are on blood thinner Eliquis, which was co-developed with <b>Pfizer</b>, and cancer immunotherapy Opdivo. Eliquis has become the leading global oral anticoagulant, with Bristol Myers recognizing nearly $9.2 billion in sales in 2020 (up 16%). Meanwhile, Opdivo's sales retraced slightly to $7 billion last year. Nevertheless, Opdivo is being examined in dozens of clinical trials as a monotherapy or combination therapy, which offers plenty of hope for future label-expansion opportunities.</p>\n<p>The bottom line is that investors can buy shares of Bristol Myers Squibb for about eight times Wall Street's forward-year consensus earnings, which is downright cheap. They'll also net a cool 3.1% dividend yield for their patience.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 19:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.\nThe reason? Over time,...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/04/16/the-smartest-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127834845","content_text":"For the past 14 months, stock market volatility has been above historic norms (thanks, coronavirus!). Despite this, all three major U.S. indexes have rocketed to all-time highs.\nThe reason? Over time, operating earnings growth drives equity valuations higher. We're never going to be able to predict what happens in the short run with any accuracy, but buying game-changing businesses and holding onto them for long periods of time tends to be a surefire moneymaking strategy.\nBut here's what most folks overlook: You don't need a gigantic pocketbook to build wealth on Wall Street. If you have $200 you can spare, which won't be needed to pay bills or cover an emergency, you have more than enough to start or further your trek toward financial independence. Here are some of the smartest stocks you can buy right now with $200.\n\nImage source: Getty Images.\nPalantir Technologies\nOne of the best ways for patient investors to put $200 to work right now would be to buy data-mining specialist Palantir Technologies (NYSE:PLTR). The company isn't exactly cheap at 42 times last year's sales but it's growing so quickly that it has a good chance to grow into its big shoes, so to speak.\nPalantir is a dual-threat company. Its Gotham platform is designed to help the U.S. government mine through copious amounts of data so it can plan missions and keep its citizens safe. Multiple branches of the U.S. government have existing or pending contracts with the company. In total, 56% of its roughly $1.1 billion in sales last year were brought in by Gotham.\nThere's also the company's Foundry platform, which provides large-scale data analytics for predominantly medium- and large-sized businesses. Without getting too deep into company speak, Foundry allows businesses to aggregate and visualize their data to better streamline their operations. Foundry ended 2020 with 24 customers in the Global 300, implying it has a long runway to land new clients.\nWhat both Gotham and Foundry bring to the table is a reliance on artificial intelligence (AI). Palantir's software solutions lean on AI to grow smarter all the time. Being able to adapt to a dynamic world and economy is what's helped Palantir hang onto its biggest clients.\nWhat should investors expect from Palantir? Look for bigger businesses to latch on, but at the same time, the company's concentration of sales from its biggest customers may decline. By mid-decade, Foundry has the potential to be Palantir's core growth driver. Sales growth could reasonably remain in the 30%+ range for much of the decade.\n\nImage source: Getty Images.\nCresco Labs\nAnother exceptionally smart way to put $200 to work right now is by focusing on U.S. marijuana stocks. Even though Canadian pot stocks are more well-known, it's the U.S. multistate operators (MSO) that have a clear path to fast double-digit growth rates and recurring profitability. The cannabis stock that looks particularly cheap at the moment is Cresco Labs (OTC:CRLBF).\nNot to sound like a broken record, but Cresco Labs is also a dual threat. On one hand, it has its retail segment, which is common for pretty much all MSOs. Not including two pending acquisitions, Cresco has 24 operational dispensaries at the moment, with 29 total licenses in its back pocket. If the aforementioned deals close, it'll have more than 30 open dispensaries and the ability to have close to four dozen retail stores.\nPerhaps the most interesting thing about Cresco's retail approach is that it's targeting a handful of limited-license markets. It's maximized its presence in Illinois (10 stores) and Ohio (5 stores), each of which caps the number of retail stores allowable in their respective states. By focusing on these limited-license markets, Cresco is giving itself the best possible chance to scoop up market share in billion-dollar markets.\nOn the other hand, Cresco has the cannabis industry's leading wholesale operations, which accounted for just over half of its 2020 sales. Wall Street appears to be discounting Cresco Labs relative to its peers because wholesale produces lower margins than retail. The thing is, Cresco's wholesale segment has access to more than 575 dispensaries in California, the largest marijuana market in the world by annual sales.\nInvestors can currently scoop up shares of Cresco for about 2.5 times forward-year sales, which is well below the industry average for U.S. MSOs. That's a big-time bargain folks shouldn't pass up.\n\nImage source: Getty Images.\nBristol Myers Squibb\nFor those of you who aren't big risk takers, consider putting your $200 to work in pharmaceutical stock Bristol Myers Squibb (NYSE:BMY). Would you be surprised if I mentioned that Bristol Myers is a dual threat, with both acquisitive and organic growth driving its top and bottom line higher?\nOn the acquisition front, Bristol Myers completed its purchase of drug developer Celgene in November 2019. Celgene primarily focused its efforts in oncology and immunology, with multiple myeloma superstar Revlimid leading the way.\nSince its approval by the U.S. Food and Drug Administration (FDA) more than a decade ago, Revlimid has been growing annually by a double-digit percentage. It has benefited from label-expansion opportunities, longer duration of use, improved cancer-screening diagnostics, and strong pricing power.\nLast year, Revlimid bought in $12.1 billion of Bristol Myers' $42.5 billion in worldwide product sales. The best part is it's protected from a full onslaught of generic competition until the end of January 2026. This gives Bristol Myers Squibb almost five more years to rake in the cash flow from this blockbuster.\nOn the organic-growth front, all eyes are on blood thinner Eliquis, which was co-developed with Pfizer, and cancer immunotherapy Opdivo. Eliquis has become the leading global oral anticoagulant, with Bristol Myers recognizing nearly $9.2 billion in sales in 2020 (up 16%). Meanwhile, Opdivo's sales retraced slightly to $7 billion last year. Nevertheless, Opdivo is being examined in dozens of clinical trials as a monotherapy or combination therapy, which offers plenty of hope for future label-expansion opportunities.\nThe bottom line is that investors can buy shares of Bristol Myers Squibb for about eight times Wall Street's forward-year consensus earnings, which is downright cheap. They'll also net a cool 3.1% dividend yield for their patience.","news_type":1},"isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9049293753,"gmtCreate":1655795467872,"gmtModify":1676535706979,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049293753","repostId":"9049202900","repostType":1,"repost":{"id":9049202900,"gmtCreate":1655794295752,"gmtModify":1676535706826,"author":{"id":"3448793367875557","authorId":"3448793367875557","name":"TechnicalHunter","avatar":"https://static.tigerbbs.com/20616c062c392e47ee8fc9107f46437d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3448793367875557","authorIdStr":"3448793367875557"},"themes":[],"title":"2 Ways to Confirm a Market Bottom & 3 Levels to Buy","htmlText":"When the Market will hit Bottom? <a href=\"https://ttm.financial/TW/9049202900\" target=\"_blank\">2 Ways to Comfirm &amp; 3 Levels to Watch</a>U.S. stocks and other stock markets fell last week after raising interest rates.The S&amp;P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&amp;P has fallen more than 23% since its January 2022 high.&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a>&nbsp;decreased&nbsp;4.78%,&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a>&nbsp;declined&nbsp;4.79%,&nbsp;YTD&nbsp;performance&nbsp;of&nbsp;each&nbsp;are,&nbsp;-24.7%,&nbsp;-17.5%&nbsp;respectively.<a target=\"_blank\" href=\"https://laohu8.com/S/XJO.AU\">$S&amp;P/ASX 200(XJO.AU)$</a> Last week performed the worst week","listText":"When the Market will hit Bottom? <a href=\"https://ttm.financial/TW/9049202900\" target=\"_blank\">2 Ways to Comfirm &amp; 3 Levels to Watch</a>U.S. stocks and other stock markets fell last week after raising interest rates.The S&amp;P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&amp;P has fallen more than 23% since its January 2022 high.&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a>&nbsp;decreased&nbsp;4.78%,&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a>&nbsp;declined&nbsp;4.79%,&nbsp;YTD&nbsp;performance&nbsp;of&nbsp;each&nbsp;are,&nbsp;-24.7%,&nbsp;-17.5%&nbsp;respectively.<a target=\"_blank\" href=\"https://laohu8.com/S/XJO.AU\">$S&amp;P/ASX 200(XJO.AU)$</a> Last week performed the worst week","text":"When the Market will hit Bottom? 2 Ways to Comfirm & 3 Levels to WatchU.S. stocks and other stock markets fell last week after raising interest rates.The S&P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&P has fallen more than 23% since its January 2022 high. $NASDAQ(.IXIC)$ decreased 4.78%, $DJIA(.DJI)$ declined 4.79%, YTD performance of each are, -24.7%, -17.5% respectively.$S&P/ASX 200(XJO.AU)$ Last week performed the worst week","images":[{"img":"https://community-static.tradeup.com/news/5403fbc4d0d6ccf9f5cc97050aa533e4","width":"1035","height":"201"},{"img":"https://community-static.tradeup.com/news/a3970d0e3842c3b440ced19bb2f56166","width":"664","height":"415"},{"img":"https://community-static.tradeup.com/news/18b0bdfae0727f344fe9d1993ba9e17b","width":"1240","height":"810"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049202900","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":562,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088090246,"gmtCreate":1650287811041,"gmtModify":1676534686938,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for easter egg change","listText":"Posting for easter egg change","text":"Posting for easter egg change","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088090246","isVote":1,"tweetType":1,"viewCount":1007,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081979173,"gmtCreate":1650188135864,"gmtModify":1676534665863,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for easter chance","listText":"Posting for easter chance","text":"Posting for easter chance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081979173","isVote":1,"tweetType":1,"viewCount":756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9083842898,"gmtCreate":1650097378570,"gmtModify":1676534647348,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Any good stocks to recommend?&nbsp;","listText":"Any good stocks to recommend?&nbsp;","text":"Any good stocks to recommend?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9083842898","isVote":1,"tweetType":1,"viewCount":954,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089442933,"gmtCreate":1650027803960,"gmtModify":1676534631595,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Test test","listText":"Test test","text":"Test test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089442933","isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}